Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

BrainsWay Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW PREMERA BLUE CROSS BLUE SHIELD POLICY EXTENDS TO BOTH ADOLESCENT AND ADULT DEPRESSION PATIENTS NEW PREMERA BLUE CROSS BLUE SHIELD POLICY EXTENDS TO BOTH ADOLESCENT AND ADULT DEPRESSION PATIENTS

BRAINSWAY ANNOUNCES FIRST COVERAGE POLICY FOR ACCELERATED DEEP TMS

OPTUM BEHAVIORAL HEALTH, A HEALTH SERVICES COMPANY WITH OVER 48 MILLION COVERED LIVES, JOINS GROWING LIST OF INSURERS NOW COVERING DEEP TMS DEPRESSION THERAPY FOR ADOLESCENTS AGED 15 AND OLDER OPTUM BEHAVIORAL HEALTH, A HEALTH SERVICES COMPANY WITH OVER 48 MILLION COVERED LIVES, JOINS GROWING LIST OF INSURERS NOW COVERING DEEP TMS DEPRESSION THERAPY FOR ADOLESCENTS AGED 15 AND OLDER

BRAINSWAY REPORTS EXPANSION OF ADOLESCENT DEPRESSION COVERAGE APPLICABLE TO DEEP TMS

BURLINGTON, MASS. AND JERUSALEM, NOV. 25, 2025 (GLOBE NEWSWIRE) -- BRAINSWAY LTD. (NASDAQ & TASE: BWAY) (BRAINSWAY OR THE COMPANY), A GLOBAL LEADER IN ADVANCED NONINVASIVE BRAIN STIMULATION TECHNOLOGIES, TODAY ANNOUNCED THAT IT WILL HOST A VIRTUAL ANALYST & INVESTOR DAY ON MONDAY, DECEMBER 1, 2025 AT 10:00 AM ET, DURING WHICH COMPANY MANAGEMENT WILL HIGHLIGHT VARIOUS ASPECTS OF BRAINSWAY'S GROWTH STRATEGY. THE EVENT WILL FEATURE OWEN SCOTT MUIR, MD, DFAACAP (CO-FOUNDER, CHIEF MEDICAL OFFICER, RADIAL), WHO WILL DISCUSS THE SIGNIFICANT UNMET NEED FOR VARIOUS CONDITIONS AND HIS CLINICAL EXPERIENCE UTILIZING DEEP TMS, AND MICHAEL GERSHENZON, CEO OF STELLA MSO, A MANAGEMENT SERVICES ORGANIZATION SERVICING MORE THAN 20 MENTAL HEALTH CLINICS ACROSS THE U.S. AND ISRAEL, WHO WILL DISCUSS HIS EXPERIENCE WORKING WITH BRAINSWAY ON BRAINSWAY'S STRATEGIC MINORITY-STAKE INVESTMENT IN STELLA. TO REGISTER, CLICK HERE.

BRAINSWAY TO HOST VIRTUAL ANALYST & INVESTOR DAY TO DISCUSS THE COMPANY'S GROWTH STRATEGY AND DEEP TMS TREATMENT DECEMBER 1, 2025

MULTICENTER, RANDOMIZED, CONTROLLED STUDY WILL EVALUATE COMPANY'S NEXT-GENERATION MULTICHANNEL TMS TECHNOLOGY IN REDUCING HEAVY DRINKING AND CRAVINGS MULTICENTER, RANDOMIZED, CONTROLLED STUDY WILL EVALUATE COMPANY'S NEXT-GENERATION MULTICHANNEL TMS TECHNOLOGY IN REDUCING HEAVY DRINKING AND CRAVINGS

BRAINSWAY LAUNCHES FIRST CLINICAL TRIAL OF DEEP TMS 360 SYSTEM FOR ALCOHOL USE DISORDER

DEEP TMS BECOMES FIRST AND ONLY TMS DEVICE CLEARED IN TREATMENT OF PATIENTS AGED 15 TO 86 SUFFERING FROM DEPRESSION DEEP TMS BECOMES FIRST AND ONLY TMS DEVICE CLEARED IN TREATMENT OF PATIENTS AGED 15 TO 86 SUFFERING FROM DEPRESSION

BRAINSWAY RECEIVES FDA CLEARANCE OF DEEP TMS AS ADJUNCT THERAPY FOR MAJOR DEPRESSIVE DISORDER (MDD) IN ADOLESCENTS AGED 15 TO 21

R EVENUE INCREASE D 29% TO $ 13.5 MILLION IN Q3 2025 AS COMPARED WITH Q 3 202 4

BRAINSWAY REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BURLINGTON, MASS. AND JERUSALEM, OCT. 28, 2025 (GLOBE NEWSWIRE) -- BRAINSWAY LTD. (NASDAQ & TASE: BWAY) (BRAINSWAY OR THE COMPANY), A GLOBAL LEADER IN ADVANCED NONINVASIVE NEUROSTIMULATION TREATMENTS FOR MENTAL HEALTH DISORDERS, TODAY ANNOUNCED THAT IT WILL REPORT ITS THIRD QUARTER 2025 FINANCIAL RESULTS, AS WELL AS OPERATIONAL HIGHLIGHTS, BEFORE THE OPEN OF THE U.S. FINANCIAL MARKETS ON TUESDAY, NOVEMBER 11, 2025. THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:30 AM EASTERN TIME TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE AN UPDATE ON BUSINESS OPERATIONS.

BRAINSWAY TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 11, 2025

R ECENT AGREEMENTS WITH TWO ADDITIONAL U.S. MENTAL HEALTH PROVIDERS BRING TOTAL TO FOUR IN 2025

BRAINSWAY ANNOUNCES ADDITIONAL MINORITY-STAKE INVESTMENTS IN LEADING U.S. MENTAL HEALTH PROVIDERS

THIS INVESTMENT MARKS BRAINSWAY'S ENTRANCE INTO THE MARKET FOR MENTAL HEALTH THERAPIES THAT CAN BE ADMINISTERED OUTSIDE OF A CLINIC, INCLUDING AT HOME

BRAINSWAY TARGETS EXPANSION OF ITS TOTAL ADDRESSABLE MARKET THROUGH A STRATEGIC INVESTMENT IN NEUROMODULATION SYSTEMS DEVELOPER, NEUROLIEF LTD.

THE INVESTMENT IS PART OF BRAINSWAY'S ONGOING STRATEGY TO ACQUIRE MINORITY POSITIONS IN LEADING U.S. MENTAL HEALTH PROVIDERS TO HELP THEM RAISE AWARENESS FOR AND EXPAND ACCESS TO TRANSFORMATIVE CARE THE INVESTMENT IS PART OF BRAINSWAY'S ONGOING STRATEGY TO ACQUIRE MINORITY POSITIONS IN LEADING U.S. MENTAL HEALTH PROVIDERS TO HELP THEM RAISE AWARENESS FOR AND EXPAND ACCESS TO TRANSFORMATIVE CARE

BRAINSWAY ACQUIRES MINORITY-STAKE IN AXIS INTEGRATED MENTAL HEALTH

ACHIEVED RECORD QUARTERLY REVENUE OF $12.6 MILLION IN Q2 2025, AN INCREASE OF 26% COMPARED TO Q2 2024 OPERATING PROFIT TOTALED $0.6 MILLION AND ADJUSTED EBITDA ROSE TO $1.5 MILLION, RAISED FULL-YEAR 2025 REVENUE AND EBITDA GUIDANCE REMAINING PERFORMANCE OBLIGATIONS INCREASED BY 25% YOY TO $62 MILLION CONFERENCE CALL TO BE HELD TODAY AT 8:30 AM ET BURLINGTON, MASS. AND JERUSALEM, AUG. 13, 2025 (GLOBE NEWSWIRE) -- BRAINSWAY LTD.

BrainsWay Ltd.

BWAY

Price

Financial Reports

No items found.

Press Releases

BrainsWay Ltd.

BWAY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BWAY